Kangji Medical Holdings Limited

DB:50J Stock Report

Market Cap: €826.2m

Kangji Medical Holdings Valuation

Is 50J undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 50J when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 50J (€0.7) is trading below our estimate of fair value (€1.34)

Significantly Below Fair Value: 50J is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 50J?

Key metric: As 50J is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 50J. This is calculated by dividing 50J's market cap by their current earnings.
What is 50J's PE Ratio?
PE Ratio11.7x
EarningsCN¥534.41m
Market CapCN¥6.23b

Price to Earnings Ratio vs Peers

How does 50J's PE Ratio compare to its peers?

The above table shows the PE ratio for 50J vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.4x
PHH2 Paul Hartmann
12.5xn/a€742.3m
EUZ Eckert & Ziegler
23.2x5.9%€831.3m
DRW3 Drägerwerk KGaA
7.2x2.0%€796.1m
RHK RHÖN-KLINIKUM
18.6x7.5%€836.7m
50J Kangji Medical Holdings
11.7x12.1%€6.7b

Price-To-Earnings vs Peers: 50J is good value based on its Price-To-Earnings Ratio (11.7x) compared to the peer average (15.4x).

Price to Earnings Ratio vs Industry

How does 50J's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
50J 11.7xIndustry Avg. 29.5xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 50J is good value based on its Price-To-Earnings Ratio (11.7x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is 50J's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

50J PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.7x
Fair PE Ratio21x

Price-To-Earnings vs Fair Ratio: 50J is good value based on its Price-To-Earnings Ratio (11.7x) compared to the estimated Fair Price-To-Earnings Ratio (21x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 50J forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.69
€1.04
+48.9%
14.9%€1.19€0.88n/a2
Nov ’25€0.67
€1.01
+51.3%
16.5%€1.17€0.84n/a2
Oct ’25€0.68
€1.01
+48.0%
16.5%€1.17€0.84n/a2
Sep ’25€0.64
€1.01
+57.3%
16.5%€1.17€0.84n/a2
Aug ’25€0.64
€1.14
+80.1%
8.9%€1.25€1.04n/a2
Jul ’25€0.64
€1.18
+86.0%
11.2%€1.31€1.05n/a2
Jun ’25€0.69
€1.18
+69.9%
11.2%€1.31€1.05n/a2
May ’25€0.84
€1.18
+40.9%
11.4%€1.32€1.05n/a2
Apr ’25€0.77
€1.18
+53.7%
11.4%€1.32€1.05n/a2
Mar ’25€0.78
€1.21
+56.6%
14.2%€1.39€1.04n/a2
Feb ’25€0.69
€1.21
+75.9%
14.2%€1.39€1.04n/a2
Jan ’25€0.79
€1.21
+53.5%
13.1%€1.37€1.05n/a2
Dec ’24€0.85
€1.21
+42.6%
13.1%€1.37€1.05n/a2
Nov ’24€0.74
€1.24
+67.1%
14.8%€1.42€1.05€0.672
Oct ’24€0.80
€1.24
+55.5%
14.8%€1.42€1.05€0.682
Sep ’24€0.80
€1.24
+54.6%
16.0%€1.44€1.04€0.642
Aug ’24€0.96
€1.46
+52.1%
13.3%€1.65€1.27€0.642
Jul ’24€0.96
€1.46
+52.1%
13.3%€1.65€1.27€0.642
Jun ’24€1.00
€1.46
+46.0%
13.3%€1.65€1.27€0.692
May ’24€1.14
€1.44
+26.3%
10.9%€1.60€1.28€0.842
Apr ’24€1.09
€1.49
+36.7%
9.5%€1.61€1.29€0.773
Mar ’24€1.13
€1.46
+29.3%
13.4%€1.60€1.18€0.783
Feb ’24€1.10
€1.03
-6.1%
13.7%€1.18€0.89€0.692
Jan ’24€0.95
€1.03
+7.7%
3.3%€1.06€0.99€0.792
Dec ’23€0.96
€1.03
+7.1%
3.3%€1.06€0.99€0.852
Nov ’23€0.81
€1.03
+26.2%
3.3%€1.06€0.99€0.742

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-5.5%

1Y

18.9%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-8.8%

1Y

-37.3%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%